<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04847206</url>
  </required_header>
  <id_info>
    <org_study_id>BASEC 2021-00405</org_study_id>
    <nct_id>NCT04847206</nct_id>
  </id_info>
  <brief_title>Effects of MDMA-like Substances in Healthy Subjects</brief_title>
  <acronym>MDMA-like</acronym>
  <official_title>Effects of MDMA-like Substances in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The serotonin (5-HT) and oxytocin releaser and so-called &quot;empathogen&quot;&#xD;
      3,4-methylenedioxymethamphetamine (MDMA) acutely produces positive feelings, empathy, and&#xD;
      trust. MDMA is used recreationally (ecstasy), as research tool to study 5-HT and oxytocin&#xD;
      function, and is investigated for MDMA-assisted psychotherapy.&#xD;
&#xD;
      MDMA is metabolized in part (10%) to the psychoactive metabolite&#xD;
      3,4-methylenedioxyamphetamine (MDA) which itself is also a recreational substance and has&#xD;
      also been used to assist psychotherapy in the past. The present study aims to describe and&#xD;
      directly compare for the first time the effects of MDMA and MDA in the same healthy&#xD;
      volunteers and using modern psychological and psychometric tests.&#xD;
&#xD;
      Additionally, although amphetamines including MDMA and MDA induce mainly positive subjective&#xD;
      effects they may also produce negative subjective drug effects including anxiety in&#xD;
      particular at the onset of the subjective response and the rapid onset of euphoria may&#xD;
      increase the risk of abuse. Additionally, blood pressure may increase rapidly at drug onset.&#xD;
      A possible solution to mitigate anxiety, abuse-related rapid euphoria increases and/or rapid&#xD;
      blood pressure changes at onset consist of slowing the onset of the drug effect by using a&#xD;
      slow-release formulation of MDMA. In the present study, the investigators will characterize&#xD;
      the effects of lysine-MDMA and lysine-MDA and compare their effects with MDMA/MDA to test the&#xD;
      concept of attenuated effects across both substances.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      3,4-methylenedioxymethamphetamine (MDMA) is used as recreational substance (Ecstasy),&#xD;
      research tool to stimulate serotonin (5-HT) and oxytocin release and study associated mood&#xD;
      states, and as a potential therapeutic substance to enhance psychotherapy for post-traumatic&#xD;
      stress disorder. MDMA is an amphetamine derivative which, unlike prototypical amphetamines,&#xD;
      predominantly enhances serotonergic neurotransmission via release of 5-HT through the SERT&#xD;
      and it less potently also releases dopamine and norepinephrine through the DA transporter and&#xD;
      NE transporter, respectively. Furthermore, MDMA is known to trigger oxytocin release which&#xD;
      may contribute to its effects to increase trust, prosociality, and enhance empathy. MDMA is&#xD;
      therefore referred to as an &quot;entactogen&quot; or &quot;empathogen&quot;. MDMA is currently the only&#xD;
      empathogen investigated in substance-assisted psychotherapy but other substances including&#xD;
      the MDMA-metabolite 3,4-methylenedioxyamphetamine (MDA) have been used in the past or may be&#xD;
      used in the future.&#xD;
&#xD;
      Aim 1: MDA may exert greater perceptual psychedelic-like effects due to a more potent binding&#xD;
      to the serotonin 5-HT2A receptor, and it may also act longer than MDMA partly due to a longer&#xD;
      plasma half-life. However, effects of MDMA and MDA have never been compared directly in the&#xD;
      same study in humans and there is only one modern study that characterized MDA in humans.&#xD;
      Therefore, the present study aims to describe and directly compare for the first time the&#xD;
      effects of MDMA and MDA in the same healthy volunteers using modern and sensitive&#xD;
      psychological and psychometric tests.&#xD;
&#xD;
      Aim 2: Additionally, although amphetamines including MDMA and MDA induce mainly positive&#xD;
      subjective effects they may also produce negative subjective drug effects including anxiety&#xD;
      in particular at the onset of the subjective response and the rapid onset of euphoria may&#xD;
      increase abuse liability. Additionally, blood pressure may increase rapidly at drug onset. A&#xD;
      possible solution to mitigate anxiety, abuse-related rapid euphoria increases and/or rapid&#xD;
      blood pressure changes at onset consist of slowing the onset of the drug effect by using a&#xD;
      slow-release formulation of MDMA/MDA. Alternatively, amphetamines can be linked to the&#xD;
      endogenous amino acid lysine forming inactive lysine-amphetamine which then liberates the&#xD;
      active amphetamine slowly in the circulation via plasma peptidases. This approach has been&#xD;
      implemented with the medication Lisdexamfetamine, which combines lysine with d-amphetamine.&#xD;
      In the present study, the investigators will similarly characterize the effects of&#xD;
      lysine-MDMA and lysine-MDA to test for attenuated effects across both substances in&#xD;
      comparison with MDMA/MDA.&#xD;
&#xD;
      Using a two-factorial study design with four active substance conditions (MDMA vs. MDA and&#xD;
      lysine-MDMA vs. lysine-MDA) the investigators will be able to test differences between MDMA&#xD;
      and MDA (with and without lysine) as well as between lysinated a non-lysinated substance&#xD;
      (regardless of active substance) in the same study and with high statistical power and within&#xD;
      one study addressing two aims.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double-blind, placebo-controlled, 5-period cross-over design with four active substance conditions (equimolar doses of psychoactive substance) and placebo:&#xD;
1. MDMA (100 mg MDMA-hydrochloride; 84.1 mg MDMA free base) 2) MDA (93.9 mg MDA-hydrochloride; 78.0 mg MDA free base) 3) lysMDMA (171.7mg lysMDMA dihydrochloride; 84.1 mg MDMA free base) 4) lysMDA (165.6 mg lysMDA dihydrochloride; 78.0 mg MDA free base) 5) Placebo</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute subjective effects I</measure>
    <time_frame>18 months</time_frame>
    <description>Visual Analog Scales (VAS) assessing the intensity and duration of subjective effects on a scale from 0 - 100 percent with higher scores representing more intense effects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma levels of MDMA</measure>
    <time_frame>18 months</time_frame>
    <description>Assessed 18 times on each study day via blood samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma levels of MDA</measure>
    <time_frame>18 months</time_frame>
    <description>Assessed 18 times on each study day via blood samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Subjective effects II</measure>
    <time_frame>18 months</time_frame>
    <description>Adjective Mood Rating Scale (AMRS) assesses the occurrence and intensity of 60 moods on a 4-point Likert scale ranging from &quot;not at all&quot; to &quot;extremely&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Subjective effects III</measure>
    <time_frame>18 months</time_frame>
    <description>5 Dimensions of Altered States of Consciousness (5D-ASC) consisting of 94 items to be rated on a visual analog scale (0-100 mm), with higher values indicating stronger effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>States of Consciousness Questionnaire</measure>
    <time_frame>18 months</time_frame>
    <description>Assesses the emergence and intensity of phenomenons occurring in altered states of consciousness on a 6-point Likert scale ranging from 0 (&quot;not at all&quot;) to 5 (&quot;extremely&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological Insight Questionnaire</measure>
    <time_frame>18 months</time_frame>
    <description>Assesses the degree of psychological insight caused by a psychedelic experience through 14-items to be answered on a 6-point Likert scale ranging from 0 (&quot;not at all&quot;) to 5 (&quot;extremely&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic effects I</measure>
    <time_frame>18 months</time_frame>
    <description>Assessed 20 times on each study day via systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic effects II</measure>
    <time_frame>18 months</time_frame>
    <description>Assessed 20 times on each study day via heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic effects III</measure>
    <time_frame>18 months</time_frame>
    <description>Assessed 20 times on each study day via tympanic body temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic effects IV</measure>
    <time_frame>18 months</time_frame>
    <description>Assessed 7 times on each study day via pupil diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic effects V</measure>
    <time_frame>18 months</time_frame>
    <description>Assessed one time on each study day via ECG (QT-time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of oxytocin</measure>
    <time_frame>18 months</time_frame>
    <description>Assessed 5 times on each study day via blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotion processing I</measure>
    <time_frame>18 months</time_frame>
    <description>Assessed one time on each study day via Face Emotion Recognition Task (FERT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotion processing II</measure>
    <time_frame>18 months</time_frame>
    <description>Assessed one time on each study day via Multifaceted Empathy Test (MET).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NEO-Five-Factor-Inventory (NEO-FFI)</measure>
    <time_frame>Baseline</time_frame>
    <description>The NEO-FFI is a self-description questionnaire with 60 items for the measurement of the &quot;big five&quot;: neuroticism, extraversion, openness, agreeableness, and consciousness. It uses a 5-point Likert scale ranging from &quot;completely disagree&quot; to &quot;fully agree&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freiburger Personality Inventory (FPI-R)</measure>
    <time_frame>Baseline</time_frame>
    <description>The FPI-R version comprises 138 items and covers 12 dimensions of personality: life satisfaction, social orientation, performance orientation, inhibition, excitability, aggressiveness, stress, physical complaints, health concerns, openness, as well as the secondary factors according to Eysenck's Extraversion and Emotionality (Neuroticism). It uses a 2-point scale (&quot;true&quot; and &quot;not true&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saarbr√ºcker Personality Questionnaire (SPF)</measure>
    <time_frame>Baseline</time_frame>
    <description>The SPF defines empathy as the &quot;reactions of one individual to the observed experiences of another.&quot; It assesses 28-items on a 5-point Likert scale ranging from &quot;Does not describe me well&quot; to &quot;Describes me very well&quot;. The measure has 4 subscales (Perspective Taking, Fantasy, Empathic Concern, Personal Distress) each made up of 7 different items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HEXACO personality inventory</measure>
    <time_frame>Baseline</time_frame>
    <description>The HEXACO personality inventory is a six-dimensional model of human personality with 100 items.The six factors are: Honesty-Humility, Emotionality, Extraversion, Agreeableness, Conscientiousness and Openness to Experience. The HEXACO uses a 5-point Likert scale ranging from &quot;completely disagree&quot; to &quot;fully agree&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Defense Style Questionnaire (DSQ-40)</measure>
    <time_frame>Baseline</time_frame>
    <description>The DSQ-40 can provide scores for 20 individual defenses, and scores for the three factors &quot;mature&quot;, &quot;neurotic&quot;, and &quot;immature&quot;. Each item is evaluated on a scale from 1 to 9, where &quot;1&quot; indicates &quot;completely disagree&quot; and &quot;9&quot; indicates &quot;fully agree&quot;.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>MDMA (100 mg MDMA-hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MDMA (100 mg MDMA-hydrochloride; 84.1 mg MDMA free base)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDA (93.9 mg MDA-hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MDA (93.9 mg MDA-hydrochloride; 78.0 mg MDA free base)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lysine-MDMA (171.7mg lysMDMA dihydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lysine-MDMA (171.7mg lysMDMA dihydrochloride; 84.1 mg MDMA free base)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lysine-MDA (165.6 mg lysMDA dihydrochloride;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lysine-MDA (165.6 mg lysMDA dihydrochloride; 78.0 mg MDA free base)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3,4-methylenedioxymethamphetamine</intervention_name>
    <description>A moderate dose of 100 mg MDMA will be administered.</description>
    <arm_group_label>MDMA (100 mg MDMA-hydrochloride)</arm_group_label>
    <other_name>MDMA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3,4-methylenedioxyamphetamine</intervention_name>
    <description>A moderate dose of 93.9 mg MDA will be administered.</description>
    <arm_group_label>MDA (93.9 mg MDA-hydrochloride)</arm_group_label>
    <other_name>MDA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lysine-3,4-methylenedioxymethamphetamine</intervention_name>
    <description>A moderate dose of 171.7 mg lysine-MDMA will be administered.</description>
    <arm_group_label>lysine-MDMA (171.7mg lysMDMA dihydrochloride</arm_group_label>
    <other_name>lysine-MDMA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lysine-3,4-methylenedioxyamphetamine</intervention_name>
    <description>A moderate dose of 165.6 mg lysine-MDA will be administered.</description>
    <arm_group_label>lysine-MDA (165.6 mg lysMDA dihydrochloride;</arm_group_label>
    <other_name>lysine-MDA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (Mannitol)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18 and 65 years old&#xD;
&#xD;
          2. Sufficient understanding of the German language&#xD;
&#xD;
          3. Understanding of procedures and risks associated with the study&#xD;
&#xD;
          4. Willing to adhere to the protocol and signing of the consent form&#xD;
&#xD;
          5. Willing to refrain from the consumption of illicit psychoactive substances during the&#xD;
             study&#xD;
&#xD;
          6. Abstaining from xanthine-based liquids from the evenings prior to the study sessions&#xD;
             to the end of the study days&#xD;
&#xD;
          7. Willing not to operate heavy machinery within 48 hours after substance administration&#xD;
&#xD;
          8. Willing to use double-barrier birth control throughout study participation&#xD;
&#xD;
          9. Body mass index between 18-29 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chronic or acute medical condition&#xD;
&#xD;
          2. Current or previous major psychiatric disorder&#xD;
&#xD;
          3. Psychotic disorder or bipolar disorder in first-degree relatives&#xD;
&#xD;
          4. Hypertension (&gt;140/90 mmHg) or hypotension (SBP&lt;85 mmHg)&#xD;
&#xD;
          5. Hallucinogenic substance or MDMA use more than 20 times or use of any illicit&#xD;
             substance within the previous two months (not including cannabis)&#xD;
&#xD;
          6. Pregnancy or current breastfeeding&#xD;
&#xD;
          7. Participation in another clinical trial (currently or within the last 30 days)&#xD;
&#xD;
          8. Use of medication that may interfere with the effects of the study medication&#xD;
&#xD;
          9. Tobacco smoking (&gt;10 cigarettes/day)&#xD;
&#xD;
         10. Consumption of alcoholic beverages (&gt;20 drinks/week)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias E Liechti, Prof. Dr. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias E Liechti, MD</last_name>
    <phone>61 328 68 68</phone>
    <phone_ext>+41</phone_ext>
    <email>matthias.liechti@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle Straumann, MSc</last_name>
    <phone>61 328 43 68</phone>
    <phone_ext>+41</phone_ext>
    <email>isabelle.straumann@usb.ch</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-Methyl-3,4-methylenedioxyamphetamine</mesh_term>
    <mesh_term>3,4-Methylenedioxyamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

